• 제목/요약/키워드: acute respiratory infection

검색결과 344건 처리시간 0.028초

급성상기도감염 항생제 처방률 공개 효과 분석 (The Effect of Public Report on Antibiotics Prescribing Rate)

  • 김수경;김희은;백미숙;이숙향
    • 한국임상약학회지
    • /
    • 제20권3호
    • /
    • pp.242-247
    • /
    • 2010
  • Controlling inappropriate antibiotics prescribing for acute upper respiratory infections(URI) is a very important for prudent use of antibiotics and resistance control. Health Insurance Review and Assessment Service (HIRA) introduced Prescribing Evaluation Program and publicly reported antibiotics prescribing rate for URI of each health institution. We performed segmented regression analysis of interrupted time series to estimate the effect of public report on antibiotics prescribing rate using national health insurance claims data. The results indicate that just before the public report period, clinics' monthly antibiotics prescribing rate for URI was 66.7%. Right after the public report, the estimated antibiotics prescribing rate dropped abruptly by 12.3%p. There was no significant changes in month-to-month trend in the prescribing rate before and after the intervention.

Coronavirus Disease 2019-Liver Injury-Literature Review and Guidelines Based on the Recommendations of Hepatological Societies

  • Pawlowska, Joanna;Lebensztejn, Dariusz M.;Jankowska, Irena
    • Pediatric Gastroenterology, Hepatology & Nutrition
    • /
    • 제24권2호
    • /
    • pp.119-126
    • /
    • 2021
  • The aim of our paper was to present current knowledge, review literature and available practice guidelines of international hepatological associations regarding the effect of severe acute respiratory syndrome coronavirus 2 coronavirus on the liver, patients with underline liver disease, awaiting on liver transplantation (LTx) or being after LTx in the pandemic coronavirus disease 2019 area.

코로나바이러스감염증-19의 바이러스 (SARS-CoV-2) 특징, 전파 및 임상 양상 (Epidemiology, Virology, and Clinical Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2; Coronavirus Disease-19))

  • 박수은
    • Pediatric Infection and Vaccine
    • /
    • 제27권1호
    • /
    • pp.1-10
    • /
    • 2020
  • 2019년 12월에 중국 후베이성 우한시에서 원인 미상 폐렴이 무리 지어 발생하기 시작하였다. 환자의 하기도에서 이전에 알려지지 않은 새로운 코로나바이러스가 분리되었으며 severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)로 명명되었다. 세계보건기구는 SARS-CoV-2에 의한 질병을 코로나바이러스감염증-19(coronavirus disease 2019, COVID-19)로 명명하였다. 2020년 3월 11일에 COVID-19는 전세계 최소 114국으로 퍼졌으며 약 4,000명이 사망하여 세계보건기구는 COVID-19가 세계적 대유행임을 선언하였다. 지난 20년 동안 새로운 코로나바이러스에 의한 두 번의 유행이 있었다. 2002-2003년 중증급성호흡기증후군(severe acute respiratory syndrome, SARS) 유행 시에는 8,098명의 확진 환자와 774명의 사망자가 발생하였으며, 2012년에 사우디 아라비아에서 시작되어 현재까지 주로 아라비아 반도에서 발생하고 있는 중동호흡기증후군(Middle East respiratory syndrome, MERS)는 2019년까지 총 2,499명의 환자와 858명의 사망자를 발생시켰다. 본 종설의 목적은 2020년 3월 12일까지 알려진 SARS-CoV-2의 특징과 전파 양상 및 COVID-19의 임상 증상을 알아보고 SARS와 MERS와의 유사점 및 차이점에 대하여 간략하게 소개하는 것이다.

메르스 감염에서 리바비린과 인터페론 사용에 대한 임상 문헌 고찰 (Ribavirin and Interferon Treatment for MERS-CoV Infection: A Clinical Literature Review)

  • 임미선
    • 약학회지
    • /
    • 제59권6호
    • /
    • pp.245-250
    • /
    • 2015
  • Middle East respiratory syndrome - coronavirus infection has posed substantial threat to public health with extremely high mortality rate in 2015. Although there are no approved novel medications for coronavirus, several antiviral agents such as ribavirin and interferon have been tried to MERS patients according to the in-vitro inhibitory effect, therapeutic effect on the animal model and experience from the severe acute respiratory syndrome - coronavirus infection. The aim of this study is to evaluate the clinical evidence of the antiviral treatment for MERS-CoV infection. After systematically searching the medical literature databases, I found five studies described the clinical efficacy of antiviral treatment on MERS patients. All of them were about the combination therapy of ribavirin and interferon (IFN). Two of them were retrospective cohort studies with quality of evidence (QOE) II and the others were observational study and case reports with QOE III. As a result of critical appraisal, it is concluded that none of those studies represented confirmatory clinical evidence of the efficacy of ribavirin and interferon combination therapy on MERS patients. Although Omrani et al. represented that ribavirin and IFN treatment had significantly improved survival at 14 days, it was not enough time to conclude the effect.

MUC1-C influences cell survival in lung adenocarcinoma Calu-3 cells after SARS-CoV-2 infection

  • Kim, Dongbum;Maharjan, Sony;Kim, Jinsoo;Park, Sangkyu;Park, Jeong-A;Park, Byoung Kwon;Lee, Younghee;Kwon, Hyung-Joo
    • BMB Reports
    • /
    • 제54권8호
    • /
    • pp.425-430
    • /
    • 2021
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces coronavirus disease 2019 (COVID-19) and may increase the risk of adverse outcomes in lung cancer patients. In this study, we investigated the expression and function of mucin 1 (MUC1) after SARS-CoV-2 infection in the lung epithelial cancer cell line Calu-3. MUC1 is a major constituent of the mucus layer in the respiratory tract and contributes to pathogen defense. SARS-CoV-2 infection induced MUC1 C-terminal subunit (MUC1-C) expression in a STAT3 activation-dependent manner. Inhibition of MUC1-C signaling increased apoptosis-related protein levels and reduced proliferation-related protein levels; however, SARS-CoV-2 replication was not affected. Together, these results suggest that increased MUC1-C expression in response to SARS-CoV-2 infection may trigger the growth of lung cancer cells, and COVID-19 may be a risk factor for lung cancer patients.

A Case of Mycobacterium massiliense Infection Presenting as Pneumonia Resistant to Antibiotics in an Immunocompetent Host

  • Yoo, Jung-Wan;Kim, Yong-Hee;Shim, Tae-Sun
    • Tuberculosis and Respiratory Diseases
    • /
    • 제69권1호
    • /
    • pp.39-42
    • /
    • 2010
  • Mycobacterium massiliense is newly identified rapid-growing nontuberculous mycobacterium, but there are no reports of this mycobacterium species being the cause of human illness. We describe one case of Mycobacterium massiliense infection presenting as antibiotic-resistant acute pneumonia that resulted in surgical treatment.

코로나-19 감염에 의한 후두 합병증 (Laryngeal Complications of the COVID-19)

  • 김근전;주영훈
    • 대한후두음성언어의학회지
    • /
    • 제33권3호
    • /
    • pp.156-159
    • /
    • 2022
  • The coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus-2 has upended the world of otolaryngology. After COVID-19 infection, patients experience various complication of symptoms due to injury of the larynx and lung/ respiratory system. Regardless of the patient's severity, patients can experience several complications including dysphonia, vocal cord paralysis/paresis and sensory neuropathy. An emerging role for otolaryngologists in the coming weeks and months is the management of laryngeal complications of COVID-19. This review is intended to describe laryngeal complications in patients recovering from COVID-19 infection.

급성 호흡기 감염증 소아에서 Human metapneumovirus 감염의 임상 양상 (Clinical features of human metapneumovirus infection in children with acute respiratory tract infections)

  • 이재숙;서현주;우정주;장성희;이진아;송미옥;박화영;안영민
    • Pediatric Infection and Vaccine
    • /
    • 제14권1호
    • /
    • pp.75-82
    • /
    • 2007
  • 목 적 : hMPV는 paramyxovirus에 속하는 RNA 바이러스로 2001년 van den Hoogen 등에 의해 처음으로 보고되었으며 늦은 겨울이나 이른 봄에 영아와 노인에서 호흡기 감염을 일으키는 바이러스로 알려져 있으나 아직 우리나라에서의 보고는 많지 않다. 최근 호흡기 증상을 보이는 환아들에서 hMPV를 확인한 바 있어 이에 보고하는 바이다. 방 법 : 2004년 10월부터 2005년 5월까지 을지병원, 서울의료원, 보라매병원 소아과에 호흡기 증상을 주소로 방문한 443명의 비인두 흡인물에서 hMPV RT-PCR을 시행하였고, 양성인 15명의 임상 양상과 검사 소견을 의무기록을 통해 후향적으로 조사하였다. 결 과 : 443명 중 15명에서 hMPV PCR 양성을 보여 양성율은 3.4%이었다. 남아가 7명, 여아가 8명이었고 연령은 1개월에서 62개월(정중값 31.5개월)이었다. 이중 24개월 미만의 환아가 53.3%(8/15)이었다. 진단명은 폐렴 9명, 모세기관지염 3명, 상기도염 2명, 후두염 1명이었다. 그 중 1명에서 천식이 있었고 나머지 환아에서는 기왕력이 없었다. 임상 증상으로는 기침이 15명(100%)으로 가장 많았고 그 외 열감 12명(80%), 콧물 10명(67%), 구토 4명(27%), 호흡 곤란 4명(27%), 설사 3명(20%), 발진 1명(7%)이 있었다. 신체 검진 상 인두 발적이 가장 흔하게 보이는 소견이었으며 나음 6례, 흉부 함몰 4례, 빈호흡 2례, 천명 2례, 천음 1례가 관찰되었다. 말초 혈액 검사만으로 hMPV 감염을 시사하는 특징적인 소견은 없었다. 15명 중 2명에서 아데노바이러스와 중복감염이 있었다. 평균 발열 기간은 $4.9{\pm}2.8$일이었으며 입원 치료를 하였던 13명의 평균 재원 기간은 $5.6{\pm}0.9$일이었고 모두 대증적 치료 후 합병증 없이 증상 호전을 보여 퇴원하였다. 결 론 : hMPV는 상기도 및 하기도 호흡기 감염의 중요 원인 바이러스 중 하나로 생각되며 우리나라에서의 임상적, 역학적 특징을 규명하기 위해서는 향후 더 많은 환자를 대상으로 한 연구가 필요할 것으로 사료된다.

  • PDF

Mycoplasma pneumoniae associated stroke in a 3-year-old girl

  • Kim, Gun-Ha;Seo, Won Hee;Je, Bo-Kyung;Eun, So-Hee
    • Clinical and Experimental Pediatrics
    • /
    • 제56권9호
    • /
    • pp.411-415
    • /
    • 2013
  • Infectious diseases precede a significant proportion of acute ischemic strokes in children. Here, we report a case of acute ischemic stroke in a 3-year-old girl with a Mycoplasma pneumonia-associated respiratory tract infection. She developed an acquired prothrombotic state of protein S deficiency and had increased fibrinogen and fibrinogen degradation product levels and increased titer of antinuclear antibodies. However, these conditions were completely alleviated at the 1-month follow-up examination. Infection with M. pneumoniae may cause a transient prothrombotic state that can potentially cause a thrombus.

Experimental Models for SARS-CoV-2 Infection

  • Kim, Taewoo;Lee, Jeong Seok;Ju, Young Seok
    • Molecules and Cells
    • /
    • 제44권6호
    • /
    • pp.377-383
    • /
    • 2021
  • Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is a novel virus that causes coronavirus disease 2019 (COVID-19). To understand the identity, functional characteristics and therapeutic targets of the virus and the diseases, appropriate infection models that recapitulate the in vivo pathophysiology of the viral infection are necessary. This article reviews the various infection models, including Vero cells, human cell lines, organoids, and animal models, and discusses their advantages and disadvantages. This knowledge will be helpful for establishing an efficient system for defense against emerging infectious diseases.